I came across this 2013 post where vitiligo symptoms were sucessfully reversed in mice.
In 2013 itself a 1 million dollar funding was given to this research.
In 2013 a patent application for a vaccine for humans was also submitted. Which can be found at -
http://www.google.com/patents/WO2013033395A1?cl=en
All I can gather was that human clinical trials were scheduled to begin from 2015. I don't know whether it has started. Info about it from you guys will be very useful in knowing the present status of this research.
I don't know whether this was discussed here earlier on this site as I joined only recently.
One of the articles on the above is quoted below-
"Loyola University of Chicago researchers have developed a genetically modified protein with potential in reversing the effects of vitiligo in mice.
The group of researchers led by Dr. Caroline Le Poole described their findings in an article published in "Science Translational Medicine"
Previous studies performed by this group of researchers have shown that the HSP70i protein plays a vital role in the autoimmune response that causes vitiligo.
HSP70i is a heat shock protein consisting of 641 building blocks called amino acids. Le Poole and her colleagues genetically modified one of these amino-acids to create a mutant HSP70i. The mutant HSP70i protein supplants HSP70i proteins, reversing the autoimmune response in vitiligo.
When administered to mice, HSP70i protein caused them to develop vitiligo. Their fur turned the colouring of salt-and-pepper. When vaccinated with the mutant HSP70i, their fur turned black again. The same effect could be observed on human skin samples.
Concerning the future of this discovery for the treatment of vitiligo, their still is a long way to go: the researchers are seeking regulatory approval and funding for clinical trials in humans."
Another research paper published by Dr. Caroline Le Poole on vitiligo in 2015 can be found at- https://www.linkedin.com/pub/caroline-le-poole/6/354/850
here she opines that since gradual cutaneous depigmentation and cytotoxic T-cell activity against melanocytes are accompanied by a paucity of regulatory T cells (Tregs) in vitiligo patient skin therefore by enhanced expression of CCL22 gene can promote Treg skin homing to suppress depigmentation.
The Funding to her research is still continuing and the total funds received till now can be found at- https://www.collectiveip.com/technology-transfer/loyola-university-...
Functioning of the T cells wrt Melonoma is well documented and various trials are underway for treatment of
melanoma by altering the functioning of these cells. Dr. Poole earlier suggested that treatment possibilities for Melonoma, vitiligo, etc can be interconnected.
I will keep looking up further and see if there is a clinical scheduled soon for vitiligo. It is however not in the list of active clinical trials at - http://www.loyolamedicine.org/loyola-medicine-clinical-trials
I live in the area and happen to see a dermatologist at the Loyola University. My dermatologists still stands by protopic and NB-UVB to be the best possible treatment currently available. However, he did mention about a fellow researcher that is looking into possible trials for vitiligo patients with melonoma medication.
He has forwarded my information to the researcher. I am still awaiting for their response. I will keep you posted.
I think this fellow is Dr Matteo Bordignon. It's not exactly a melanoma medication but a inhibitor of MIA (Melanoma inhibitory activity). I.e,, an inhibitor of the melanoma inhibitory activity.
Sounds confusing...
More details at: www.vitiligomap.com (section "Brief Description About MIA")
At vitiligomap.com I did find a reference to Dr Bordignon but not much details about his research.
That researcher is Dr. Michael Nishimura who is doing it on Melanoma patients and some other Clinal Trial may also be under progress if we take the reply of rsblr into account.
"Dr. Matteo Bordignon (the Italian researcher who discovered the role of MIA in non-segmental vitiligo) is currently trying to develop a cure based on the inhibition of the MIA protein. We really hope it will be available as soon as possible."
Rsblr,
Recruitment for one such clinical trial is being done at Loyola University to study the tolerance of T-cells administered to melanoma patients. http://www.loyolamedicine.org/clinical-trials/adoptive-immunotherap...
15 persons have recruited so far for that trial.
Whether your information was forwarded to the same researcher- Dr Michael Nishimura?
It may also be some other trial.
Its great to hear from you that something of the sort is indeed happening.
Thanks.
Replies
https://www.linkedin.com/pub/caroline-le-poole/6/354/850
here she opines that since gradual cutaneous depigmentation and cytotoxic T-cell activity against melanocytes are accompanied by a paucity of regulatory T cells (Tregs) in vitiligo patient skin therefore by enhanced expression of CCL22 gene can promote Treg skin homing to suppress depigmentation.
The Funding to her research is still continuing and the total funds received till now can be found at-
https://www.collectiveip.com/technology-transfer/loyola-university-...
Functioning of the T cells wrt Melonoma is well documented and various trials are underway for treatment of
melanoma by altering the functioning of these cells. Dr. Poole earlier suggested that treatment possibilities for Melonoma, vitiligo, etc can be interconnected.
I will keep looking up further and see if there is a clinical scheduled soon for vitiligo. It is however not in the list of active clinical trials at -
http://www.loyolamedicine.org/loyola-medicine-clinical-trials
Saurabh,
I live in the area and happen to see a dermatologist at the Loyola University. My dermatologists still stands by protopic and NB-UVB to be the best possible treatment currently available. However, he did mention about a fellow researcher that is looking into possible trials for vitiligo patients with melonoma medication.
He has forwarded my information to the researcher. I am still awaiting for their response. I will keep you posted.
I think this fellow is Dr Matteo Bordignon. It's not exactly a melanoma medication but a inhibitor of MIA (Melanoma inhibitory activity). I.e,, an inhibitor of the melanoma inhibitory activity.
Sounds confusing...
More details at: www.vitiligomap.com (section "Brief Description About MIA")
If not then he is not that person for sure.
No yet. He is willing to do.
So, who is this Doctor?
That researcher is Dr. Michael Nishimura who is doing it on Melanoma patients and some other Clinal Trial may also be under progress if we take the reply of rsblr into account.
Ok about Dr. Michael. Thanks.
Regards vitiligomap.com, there are a few references to him.
1) http://www.vitiligomap.com
"Dr. Matteo Bordignon (the Italian researcher who discovered the role of MIA in non-segmental vitiligo) is currently trying to develop a cure based on the inhibition of the MIA protein. We really hope it will be available as soon as possible."
2) Also his paper.
http://www.vitiligomap.com/pdfs/MIA%20%28MELANOMA%20INHIBITORY%20AC...
Recruitment for one such clinical trial is being done at Loyola University to study the tolerance of T-cells administered to melanoma patients. http://www.loyolamedicine.org/clinical-trials/adoptive-immunotherap...
15 persons have recruited so far for that trial.
Whether your information was forwarded to the same researcher- Dr Michael Nishimura?
It may also be some other trial.
Its great to hear from you that something of the sort is indeed happening.
Thanks.
http://www.vitiligofriends.org/forum/topics/interview-with-dr-carol...
Steve can you know the latest from her? Like if the clinical trials have begun or are they recruiting?
Thanks.